Clinical Trial to Evaluate the Safety and Efficacy of Scalp Med in Treatment of Patients with Androgenetic Alopecia

    January 2008 in “ Journal of Clinical Dermatology
    Bark-Lynn Lew, Woo-Young Sim, Chang Hun Huh, Jang-Kyu Park
    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Studysummary This study found that a new topical agent, Scalp medⓇ, significantly improved hair count and thickness in men with androgenetic alopecia after 24 weeks of treatment. Our plain-language summary of this paper — not a Tressless recommendation.
    The clinical trial evaluated the safety and efficacy of Scalp medⓇ, a topical solution containing minoxidil, retinol, polysorbate 80, and phytosterol, in treating androgenetic alopecia (AGA) in males aged 20 to 60 with mild to moderate AGA. Over 24 weeks, the study demonstrated significant improvements in hair count and thickness in all participants, establishing Scalp medⓇ as an effective and safe treatment for AGA.
    Discuss this study in the Community →